Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | September 30, 2022 | October 03, 2022 |
| ObsEva SAOBSV · Entity 114543 | Director · Chief Executive Officer | January 01, 2023 | January 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Indaptus Therapeutics, Inc.
Report date September 30, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2032-09-30 | Direct | 13,750 |
Reported balance
After 2022-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-30 · Grant · Acquired 13,750 · Balance 13,750 F1: The stock option vests and becomes exercisable on September 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on September 30, 2023.
ObsEva SA
Report date January 01, 2023 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2030-11-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: One-fourth (1/4th) of the shares underlying the option vested on November 9, 2021, and the remainder of the shares underlying the option vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2030-11-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The shares underlying the option will vest on November 9, 2023, subject to the Reporting Person's continuous service. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2031-02-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: One-fourth (1/4th) of the shares underlying the option vested on February 4, 2022, and the remainder of the shares underlying the option vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2032-02-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: One-fourth (1/4th) of the shares underlying the option will vest on February 2, 2023, and the remainder of the shares underlying the option will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares underlying the option vested on November 9, 2021, and the remainder of the shares underlying the option vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2: The shares underlying the option will vest on November 9, 2023, subject to the Reporting Person's continuous service.
F3: One-fourth (1/4th) of the shares underlying the option vested on February 4, 2022, and the remainder of the shares underlying the option vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F4: One-fourth (1/4th) of the shares underlying the option will vest on February 2, 2023, and the remainder of the shares underlying the option will vest in 36 equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:10 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001193125-26-267533 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 12 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F8 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 11 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F8 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $15.36 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 10 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 9 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $32.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 8 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F5 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 7 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F5 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $39.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 6 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 5 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,810 | Not disclosed Strike: $60.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 4 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,810 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,810 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 3 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,810 Underlying: Common Stock · 1,810 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,393 | Not disclosed Strike: $180.20 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 2 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,393 shares Expires 2031-11-16 F2 · price: The reporting person agreed to cancellation of an option granted on November 17, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,393 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321150 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,393 Underlying: Common Stock · 1,393 shares Expires 2031-11-16 F2 · price: The reporting person agreed to cancellation of an option granted on November 17, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 27, 2025 Filed Jul 2, 2025 20:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0000950170-25-092937 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F1 · derivative.exercise_price: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F2 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. F1 · derivative.underlying_shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · balance_after: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:56 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073898 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-037113 · doc4.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001493152-22-027434 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2032-09-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on September 30, 2023. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:24 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-22-036086 · doc4.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:24 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 14,071 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012466 · doc4.xml · derivative · entry 2 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,071 Underlying: Common Stock · 14,071 shares Expires 2032-03-23 F2 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:24 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,140 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012466 · doc4.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,140 Underlying: Common Stock · 22,140 shares Expires 2032-03-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of November 17, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 22:28 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 27,860 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-21-065887 · doc4.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,860 Underlying: Common Stock · 27,860 shares Expires 2031-11-16 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of November 17, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 21:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001493152-21-018903 · ownership.xml · derivative · entry 1 O'CALLAGHAN BRIAN · CIK 0001415015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2031-08-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on August 4, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.